Feeds › Merger clearances (HSR)
Merger clearances (HSR)
Mergers and acquisitions the FTC and Justice Department cleared early under the Hart-Scott-Rodino Act, with the public companies among them. Granted requests only.
About this data
- What it is
- Companies planning a merger or acquisition above a size threshold must tell the FTC and the Justice Department first and wait 30 days before closing (the Hart-Scott-Rodino Act). The parties can ask for that wait to end early, and when the agencies agree, the FTC publishes an early termination notice. This feed lists those notices: the buyer, the target, the entities being acquired and the day early termination was granted. We match each name to a public company when it lines up.
- Who files it
- The FTC, which publishes a notice once it and the Department of Justice have granted the request.
- How current
- We check the FTC's list every day. A notice is published when early termination is granted, which is before the deal closes.
- Terms
- Hart-Scott-RodinoThe Hart-Scott-Rodino Act requires companies planning a merger or acquisition above a size threshold to tell the FTC and the Justice Department first and wait 30 days before closing, so the agencies can look for competition problems.Early terminationThe parties can ask for that waiting period to end sooner. When the agencies agree, the FTC publishes an early termination notice. It means the deal was cleared to close early, not that the agencies endorse it.Possible matchWe match each name to a public company automatically. A name that matches closely is shown as a company; a looser match is marked "possible match" because a similar name, a subsidiary or a differently spelled name can be matched wrongly. Most parties are private companies and funds and have no match.
- Worth knowing
- This is a partial list of deals, not every merger. Only requests that were granted appear: deals that waited out the full 30 days, deals whose request was refused and deals that were never reportable are not listed. The FTC granted no early terminations from February 2021 until the new HSR form took effect in February 2025, so there is nothing between those dates. A notice does not mean the agencies endorse a deal, and it does not say whether the deal closed. Most buyers and targets are private companies, funds or people. We match names to public companies automatically; a looser match is marked "possible match" because a similar name, a subsidiary or a differently spelled name can be matched wrongly.
This comes from the FTC's list of early-termination notices.
Source and freshness · Information, not investment advice (disclaimer).
Early terminations granted per month, last 24 months
Only granted requests are listed, not every deal. The FTC granted none from February 2021 until the new HSR form took effect in February 2025.
Latest early terminations granted
Showing: ticker BMY
Only early terminations that were granted are listed, not every deal, and none were granted between February 2021 and February 2025.
| Granted | BuyerThe "acquiring person" in the filing: the ultimate parent entity of the buyer, which can be a company, a fund or a person. We match each name to a public company automatically. A name that matches closely is shown as a company; a looser match is marked "possible match" because a similar name, a subsidiary or a differently spelled name can be matched wrongly. Most parties are private companies and funds and have no match. | TargetThe "acquired person": the ultimate parent entity of the target. The entities actually being acquired are listed under it. | Transaction | Source |
|---|---|---|---|---|
| Jun 30, 2026 | Bristol-Myers Squibb Company | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 20261580 | FTC ↗ |
| Dec 2, 2025 | Bristol-Myers Squibb Company | Orbital Therapeutics, Inc. | 20260201 | FTC ↗ |
| Nov 15, 2019 | Bristol-Myers Squibb Company | Celgene Corporation | 20190706 | FTC ↗ |
| Feb 25, 2019 | Starboard Value and Opportunity Fund Ltd. | Bristol-Myers Squibb Company | 20190797 | FTC ↗ |
| Aug 28, 2017 | Bristol-Myers Squibb Company | IFM Therapeutics, Inc. | 20171793 | FTC ↗ |
| Feb 17, 2017 | JANA Nirvana Offshore Fund, Ltd. | Bristol-Myers Squibb Company | 20170685 | FTC ↗ |
| Feb 17, 2017 | JANA Offshore Partners, Ltd. | Bristol-Myers Squibb Company | 20170684 | FTC ↗ |
| Feb 3, 2017 | Bristol-Myers Squibb Company | Illumina, Inc. GRAIL, Inc. | 20170617 | FTC ↗ |
| Dec 3, 2015 | Bristol-Myers Squibb Company | Cardioxyl Pharmceuticals, Inc. | 20160307 | FTC ↗ |
| Nov 10, 2015 | Bristol-Myers Squibb Company | Five Prime Therapeutics, Inc. | 20160152 | FTC ↗ |
| May 13, 2015 | Eli Lilly and Company | Bristol-Myers Squibb Company | 20150934 | FTC ↗ |
| Feb 11, 2015 | AstraZeneca plc | Bristol-Myers Squibb Company | 20150511 | FTC ↗ |
| Jan 21, 2015 | Bristol-Myers Squibb Company | California Institute for Biomedical Research | 20150433 | FTC ↗ |
| Jan 8, 2014 | AstraZeneca plc | Bristol-Myers Squibb Company BMS Holdco, Inc.; Amylin Pharmaceuticals, LLC | 20140375 | FTC ↗ |
| Jan 4, 2013 | The Medicines Company | Bristol-Myers Squibb Company | 20130479 | FTC ↗ |
| Mar 23, 2010 | Bristol-Myers Squibb Company | Allergan, Inc. Allergan Sales, LLC | 20100484 | FTC ↗ |
| Dec 1, 2009 | Bristol-Myers Squibb Company | Alder Biopharmaceuticals Inc. AlderBio Holdings, LLC | 20100138 | FTC ↗ |
| Sep 4, 2008 | Bristol-Myers Squibb Company | PDL BioPharma, Inc. | 20081662 | FTC ↗ |
| Jun 11, 2008 | NC VII Limited | Bristol-Myers Squibb Company ConvaTec | 20081251 | FTC ↗ |
| Jan 7, 2008 | Avista Capital Partners, L.P. | Bristol-Myers Squibb Company Bristol-Myers Squibb Medical Imaging, Inc.; Bristol-Myers Squibb Radi… | 20080450 | FTC ↗ |
| Oct 11, 2007 | Bristol-Myers Sqibb Company BMY possible match | Adnexus Therapeutics, Inc. | 20072169 | FTC ↗ |
| Mar 23, 2006 | Cadence Pharmaceuticals, Inc. | Bristol-Myers Squibb Company | 20060696 | FTC ↗ |
| Aug 16, 2005 | Novartis AG | Bristol Myers Squibb Company | 20051327 | FTC ↗ |
| Jan 7, 2005 | J.P. Morgan Chase & Co. JPM possible match | Bristol-Myers Squibb Company Bristol-Myers Oncology Therapeutics Network, Inc.; OTN Parent Corp. | 20050423 | FTC ↗ |
| May 7, 2004 | Bristol-Myers Squibb Company | Mr. Pierre Fabre Pierre Fabre Medicament S.A. | 20040769 | FTC ↗ |
| Apr 15, 2003 | Bristol-Myers Squibb Company | OPR Development, L.P. | 20030502 | FTC ↗ |
| Dec 28, 2001 | Nestle S.A. | Bristol-Myers Squibb Company | 20020225 | FTC ↗ |
| Dec 28, 2001 | L. Bettencourt | Bristol-Myers Squibb Company | 20020226 | FTC ↗ |
| May 25, 2000 | L. Bettencourt | Bristol-Myers Squibb Company Matrix Essentials, Inc. | 20002963 | FTC ↗ |
| Feb 8, 2000 | Warner Chilcott Public Limited Company | Bristol-Myers Squibb Company | 20001459 | FTC ↗ |
| Jan 21, 2000 | Bristol-Myers-Squibb Company | OXiGENE, Inc. OXiGENE, Europe, AB | 20001231 | FTC ↗ |
| Jun 21, 1999 | HPD Holdings Corp. | Bristol-Myers Squibb Company | 19993108 | FTC ↗ |
32 items, most recent first (up to 50). Each row links to the FTC page that lists the notices; the transaction number identifies it there. Updated Nov 15, 2026, 5:32 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances